Founded in Seoul in 2001, Jeisys Medical is a global leader in non-invasive aesthetic medical devices, specialized in skin care and commonly referred to as “Energy-Based Devices” (EBD). These innovative technologies rejuvenate the skin, treat scars, dissolve fat cells, remove hair and enable body reshaping using various forms of energy: lasers, pulsed light, radiofrequency and ultrasound. The EBD approach considerably reduces the use of needles, thus limiting discomfort and downtime for patients.

 

Jeisys has recorded impressive sales growth of 44% per year over the past three years, reaching KRW 143 billion (€97 million), with an EBITDA of KRW 41 billion (€28 million). The company is now the leading supplier of EBD in Japan, considered the world's most advanced market for aesthetic medicine.

​

NiXEN has chosen to participate in this transaction as a co-investor alongside ARCHIMED, in order to support the management team in the next stages of the company's development, notably international growth and expansion.​

​
“ARCHIMED’s international expertise in our industry make them the best partner for this company’s future [...] With ARCHIMED by our side, we’ll be able to pursue aggressive growth in international markets.”

​

Dong Hwan Kang, CEO and founder of Jeisys Medical
(Source : ARCHIMED)